Charles Sawyers

Charles Sawyers is a Professor at the Weill Cornell Graduate School of Medical Sciences and a leading researcher at the Sloan Kettering Institute, Memorial Sloan Kettering Cancer Center. His work bridges fundamental cancer biology and clinical translation, focusing on signaling pathways that drive tumor growth in chronic myeloid leukemia, prostate cancer, and glioblastoma.

His research has revolutionized the treatment of CML through the development and optimization of tyrosine kinase inhibitors, and he continues to pioneer strategies to overcome drug resistance in advanced cancers. Dr. Sawyers' interdisciplinary approach integrates molecular biology, pharmacology, and systems biology to identify new therapeutic targets.

The trends in his research, though not detailed in specific publications here, consistently emphasize precision medicine, oncogenic signaling networks, and the molecular evolution of therapy-resistant cancers. His work lies at the intersection of basic science and clinical innovation, impacting both patient care and drug development.

• Member, National Academy of Sciences
• Howard Hughes Medical Institute Investigator (former)
• Recipient of multiple prestigious awards in oncology and translational medicine (inferred from external knowledge, not listed here)

Dr. Sawyers has advised numerous PhD students and postdoctoral fellows through the Tri-Institutional programs and has led major research grants from the NIH, NCI, and private foundations supporting his work in cancer therapeutics. He plays a key role in shaping translational research policy and training the next generation of physician-scientists.

He leads a research laboratory at the Sloan Kettering Institute, where his team investigates mechanisms of oncogene addiction, tumor evolution, and novel therapeutic interventions in solid and hematologic malignancies.